Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC.

Bioinformatics. 2014 Sep 1;30(17):2393-8. doi: 10.1093/bioinformatics/btu323. Epub 2014 May 7.

2.

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.

Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.

3.

Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.

Choi JM, Jang JY, Choi YR, Kim HR, Cho BC, Lee HW.

Lung Cancer. 2015 Nov;90(2):175-81. doi: 10.1016/j.lungcan.2015.08.019. Epub 2015 Sep 3.

PMID:
26342551
4.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.

5.

Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.

Tsai CM, Chen JT, Chiu CH, Lai CL, Hsiao SY, Chang KT.

Lung Cancer. 2013 Nov;82(2):305-12. doi: 10.1016/j.lungcan.2013.08.028. Epub 2013 Sep 8.

PMID:
24055492
6.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.

Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

7.

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.

Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.

PLoS One. 2015 Nov 18;10(11):e0143333. doi: 10.1371/journal.pone.0143333. eCollection 2015.

8.
9.

Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.

Ma P, Zhang M, Nie F, Huang Z, He J, Li W, Han L.

Biomed Pharmacother. 2017 Mar;87:20-26. doi: 10.1016/j.biopha.2016.12.079. Epub 2016 Dec 29.

PMID:
28040594
10.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

11.

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.

Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.

J Cancer Res Clin Oncol. 2012 Dec;138(12):2069-77. doi: 10.1007/s00432-012-1291-2. Epub 2012 Jul 22.

PMID:
22821179
12.

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.

Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB.

Lung Cancer. 2014 Jan;83(1):37-43. doi: 10.1016/j.lungcan.2013.09.019. Epub 2013 Oct 14.

13.

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.

14.

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.

Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.

Cancer Chemother Pharmacol. 2012 Nov;70(5):707-16. doi: 10.1007/s00280-012-1946-3. Epub 2012 Sep 2.

PMID:
22941374
15.
16.

Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.

Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.

Int J Oncol. 2013 Jun;42(6):2094-102. doi: 10.3892/ijo.2013.1895. Epub 2013 Apr 12.

PMID:
23588221
17.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
18.
19.

Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.

Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.

Mol Cancer Ther. 2010 Jun;9(6):1647-56. doi: 10.1158/1535-7163.MCT-09-1009. Epub 2010 Jun 8.

20.

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.

Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.

PMID:
26349474

Supplemental Content

Support Center